ADC Therapeutics SA revenue
ADC Therapeutics SA's revenue was $81.4m in fiscal 2025, up 14.9% on the year before. Since fiscal 2022 ($210m) it has grown at a compound -27.1% a year. Over the last twelve months it was $79.6m.
Revenue history
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Products | $73.6M | 90.4% | ▲ 6.2% |
| License and Royalty Revenue | $7.8M | 9.6% | ▲ 401.3% |
| License Revenues (part of License and Royalty Revenue) | $5M | 64.1% | — |
| Royalty Revenue (part of License and Royalty Revenue) | $2.8M | 35.9% | ▲ 80.2% |
| Region | Revenue | Share | YoY |
|---|---|---|---|
| United States | $73.6M | 90.4% | ▲ 6.2% |
| EMEA | $7.8M | 9.6% | ▲ 401.3% |
From ADC Therapeutics SA's 10-K filed March 10, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| ADC Therapeutics SA | $79.6m | 3.0% | — |
| Ascentage Pharma Group International | $79.9m | -41.4% | — |
| Protalix Biotherapeutics, Inc. | $80.6m | 30.1% | 6.1% |
| Bicycle Therapeutics PLC | $83.5m | 194.7% | 49.8% |
| Assembly Biosciences, Inc. | $74.8m | 125.1% | -3.3% |
| Compugen LTD | $72.8m | 161.1% | 302.6% |
Compare with peers
- Ascentage Pharma Group International revenue
- Protalix Biotherapeutics, Inc. revenue
- Bicycle Therapeutics PLC revenue
- Assembly Biosciences, Inc. revenue
- Compugen LTD revenue
Head to head: AAPG vs ADCTADCT vs PLXADCT vs BCYC
More: Biotechnology stocks compared, Health Care sector, rankings of US companies